Napredna pretraga

Pregled bibliografske jedinice broj: 571617

Three novel BRCA1/BRCA2 mutations in breast/ovarian cancer families in Croatia


Levanat, Sonja; Musani, Vesna; Levačić Cvok, Mirela; Sušac, Ilona; Sabol, Maja; Ozretić, Petar; Car, Diana; Eljuga, Domagoj; Eljuga, Ljerka; Eljuga, Damir
Three novel BRCA1/BRCA2 mutations in breast/ovarian cancer families in Croatia // Gene, 498 (2012), 2; 169-176 doi:10.1016/j.gene.2012.02.010 (međunarodna recenzija, članak, znanstveni)


Naslov
Three novel BRCA1/BRCA2 mutations in breast/ovarian cancer families in Croatia

Autori
Levanat, Sonja ; Musani, Vesna ; Levačić Cvok, Mirela ; Sušac, Ilona ; Sabol, Maja ; Ozretić, Petar ; Car, Diana ; Eljuga, Domagoj ; Eljuga, Ljerka ; Eljuga, Damir

Izvornik
Gene (0378-1119) 498 (2012), 2; 169-176

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
BRCA1; BRCA2; hereditary breast/ovarian cancer; High-resolution melting analysis; Quantitative multiplex PCR of short fluorescent fragments

Sažetak
BRCA1 and BRCA2 genes from 167 candidates (145 families) were scanned for mutations. We identified 14 pathogenic point mutations in 17 candidates, 9 in BRCA1 and 5 in BRCA2. Of those, 11 have been previously described and three were novel (c.5335 C > T in BRCA1, and c.4139_4140dupTT and c.8175 G > A in BRCA2). No large deletions or duplications involving BRCA1 and BRCA2 genes were identified. No founder mutations were detected for the Croatian population. Croatia shares most of the mutations with neighboring Slovenia and also with Germany, Austria and Poland. Two common sequence variants in BRCA1, c.2077 G > A and c.4956 G > A, were found more frequently in mutation carriers compared to healthy controls. No difference in BRCA2 variants was detected between the groups. Haplotype inference showed no difference in haplotype distributions between deleterious mutation carriers and non-carriers in neither BRCA1 nor BRCA2. In silico analyses identified one BRCA1 sequence variant (c.4039A > G) and two BRCA2 variants (c.5986 G > A and c.6884 G > C) as harmful with high probability, and inconclusive results were obtained for our novel BRCA2 variant c.3864_3866delTAA. Combination of QMPSF and HRMA methods provides high detection rate and complete coverage of BRCA1/2 genes. Benefit of BRCA1/2 mutation testing is clear, since we detected mutations in young unaffected women, who will be closely monitored for breast and ovarian cancer.

Izvorni jezik
Engleski

Znanstvena područja
Temeljne medicinske znanosti



POVEZANOST RADA


Projekt / tema
098-0982464-2461 - Prijenos signala u tumorima: Hh-Gli put, interakcije i potencijalne terapije (Sonja Levanat, )

Ustanove
Institut "Ruđer Bošković", Zagreb,
KBC "Sestre Milosrdnice",
Klinički bolnički centar Zagreb

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE


Uključenost u ostale bibliografske baze podataka:


  • BIOSIS Previews (Biological Abstracts)
  • EMBASE (Excerpta Medica)
  • MEDLINE
  • Chemical Abstracts
  • EMBiology
  • Reference Update


Citati